Liraglutide: Clinical pharmacology and considerations for therapy

Pharmacotherapy

Volumn 31, Issue 9, 2011, Pages 896-911

  Sisson, Evan M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

GLP 1; Glucagon like peptide 1; Incretin; Liraglutide; Pharmacology; Safety; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ALBUMIN; ANTIDIABETIC AGENT; ATORVASTATIN; CJC 1134 PC; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; EXENDIN 4 ANTIBODY; FATTY ACID; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GRISEOFULVIN; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PLACEBO; PROTEIN ANTIBODY; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE PANCREATITIS; AMINO ACID SUBSTITUTION; ANTIBODY TITER; APOPTOSIS; AREA UNDER THE CURVE; BODY MASS; CANCER RISK; CARDIOVASCULAR EFFECT; COMBINATION CHEMOTHERAPY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EXOCYTOSIS; GASTROINTESTINAL SYMPTOM; GENDER; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAL; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; SATIETY; SEQUENCE HOMOLOGY; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH PH; SYSTOLIC BLOOD PRESSURE; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 80052254602     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.9.896     Document Type: Review

References (82)

1. Frias JP, Edelman SV. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes 2007;14:269-76. (Pubitemid 47067110)
2. Deacon CF. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007;9(suppl 1):23-31. (Pubitemid 47433966)
3. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206.
4. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992;35:701-11.
5. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122:S3-10.
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7. (Pubitemid 23037285)
7. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2008;297:127-36.
8. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003;19:141-50. (Pubitemid 36668041)
9. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4. (Pubitemid 36115169)
10. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53:2181-9. (Pubitemid 39145569)
11. Boyle PJ, Freeman JS. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus. J Am Osteopath Assoc 2007;107(suppl):S10-16.
12. Amylin Pharmaceuticals, Inc. Byetta (exenatide injection) prescribing information. San Diego, CA; 2010.
13. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35. (Pubitemid 39441462)
14. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100. (Pubitemid 40616618)
15. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91. (Pubitemid 40616617)
16. Gonzalez C, Beruto V, Keller G, Santoro S, Di GG. Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Invest Drugs 2006;15:887-95. (Pubitemid 44177842)
17. St Onge EL, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther 2010;10:801-6.
18. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ. An overview of once-weekly GLP-1 receptor agonists: available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011;13:394-407.
19. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27:1024-32.
20. Ahren B. GLP-1 for type 2 diabetes. Exp Cell Res 2011;317: 1239-45.
21. Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10:124-32.
22. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10.
23. De Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006;38:845-59. (Pubitemid 43363416)
24. Crepaldi G, Carruba M, Comaschi M, Del PS, Frajese G, Paolisso G. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management. J Endocrinol Invest 2007;30:610-14. (Pubitemid 47577816)
25. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Invest Drugs 2008;9:402-13. (Pubitemid 351507666)
26. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56. (Erratum in Lancet 2010;376:234.)
27. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9.
28. Raun K, von VP, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8-15.
29. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12.
30. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-9. (Pubitemid 30304999)
31. Novo Nordisk Inc. Victoza (liraglutide [rDNA origin] injection, solution for subcutaneous use) prescribing information. Princeton, NJ; 2010.
32. Madsen K, Knudsen LB, Agersoe H, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007;50:6126-32.
33. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006;46:635-41.
34. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 2005;330: 577-84. (Pubitemid 40417684)
35. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
36. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009;52:2046-55.
37. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404. (Pubitemid 41071152)
38. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract]. Diabetes 2008;57(suppl 1):abstract 552-P.
39. Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population pharmacokinetics of liraglutide, a once-daily human glucagonlike peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol 2010;50:886-94.
40. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202. (Pubitemid 34208381)
41. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-9. (Pubitemid 34764798)
42. Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol 2011;51:951-5.
43. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human GLP-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Disposition 2010;38:1944-53.
44. Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010;70:807-14.
45. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.
46. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide [published online ahead of print December 6, 2010]. Endocr Pract. Available from http://dx.doi.org/10.4158/ EP10215.OR.
47. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152-6. (Pubitemid 351293400)
48. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94. (Pubitemid 38569002)
49. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19. (Pubitemid 15018832)
50. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2. (Pubitemid 28549174)
51. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the longacting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42. (Pubitemid 38679980)
52. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a longacting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007;30:1608-10. (Pubitemid 46871185)
53. Roder M, Porte D Jr, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:604-8. (Pubitemid 28496546)
54. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
55. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
56. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
57. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
58. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Invest Drugs 2007;16:231-7. (Pubitemid 46206637)
59. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007;30:2032-3. (Pubitemid 47219415)
60. Harder H, Nielsen L, Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21. (Pubitemid 38989232)
61. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005;22:1016-23. (Pubitemid 41025998)
62. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-23. (Pubitemid 44620484)
63. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3.
64. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72.
65. Schmitz O, Russell-Jones D, Shaw J, et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline [abstract]. Diabetologia 2008;51(suppl 1):abstract 888.
66. Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract Res Clin Endocrinol Metab 2007;21:497-516. (Pubitemid 350177567)
67. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9.
68. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83.
69. Fonseca V, DeVries H, Henry R, Jensen K, Falahati A, Plutzky J. The GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes: a meta-analysis of six randomized clinical trials. Circulation, in press.
70. Malm-Erjefalt M, Ekblom M, Brondsted L, Vouis J, Lennernas H, Zdravkovic M. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects [abstract]. Diabetes 2008;57(suppl 1):abstract 434-P.
71. Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol [abstract]. Diabetes 2008;57(suppl 1):abstract 2145-PO.
72. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide - a once-daily GLP-1 analog - does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug [published online ahead of print January 12, 2001]. J Clin Pharmacol. Available from http://dx.doi.org/10.1177/0091270010389471.
73. Malm-Erjefalt M, Brondsted L, Zdravkovic M. The effect of liraglutide on intragastric pH in healthy human subjects [abstract]. Diabetes 2008;57(suppl 1):abstract 2144-PO.
74. Boyle PJ, Zrebiec J. Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. Diabetes Metab Res Rev 2008;24:257-85. (Pubitemid 351802792)
75. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8.
76. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals: exenatide (marketed as Byetta)-8/2008 update. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm 124713.htm. Accessed August 31, 2008.
77. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86.
78. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7.
79. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450-5.
80. Jacobson DA, Westenbroek R, Catterall WA, Philipson LH. Secretagogue modulation of islet electrical activity through calcium channel phosphorylation [abstract]. Diabetes 2008;57(suppl 1):abstract 1638-P.
81. Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP- 1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49:1353-62.
82. Novo Nordisk Inc. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results - a long term evaluation (LEADER). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=NCT01179048&rank=1. Accessed June 24, 2011.